patient portal
circular dots
nurse and elderly man looking at each other

Introduction

Tuberculosis (TB) remains a global health challenge, affecting millions of people each year. While active TB disease is well-known, latent tuberculosis infection (LTBI) often goes unnoticed, despite being a significant reservoir for future TB cases. Early detection and management of LTBI are crucial for reducing the burden of active TB cases. This article aims to shed light on the importance of testing for latent tuberculosis infection, its significance, and the available testing methods.

What is Latent Tuberculosis Infection?

Latent tuberculosis infection refers to the condition in which a person carries the bacteria Mycobacterium tuberculosis (M. tuberculosis) in their body but does not show any symptoms of active TB disease. Individuals with LTBI are not contagious and cannot spread the infection to others. However, if not properly managed, LTBI can progress to active TB disease, which is characterized by severe symptoms and the potential to spread to others.

The Importance of LTBI Testing

Detecting and treating LTBI is a critical strategy in the global fight against TB. By identifying individuals with LTBI and providing appropriate treatment, healthcare systems can prevent the development of active TB disease. This approach not only protects individuals from the potential health risks of TB but also reduces the overall pool of potential TB cases, leading to a decrease in transmission rates and ultimately lowering the burden of TB in communities.

LTBI Testing Methods

Several testing methods are available for diagnosing latent tuberculosis infection. These methods are categorized into two main types: tuberculin skin tests (TST) and interferon-gamma release assays (IGRAs).

  1. Tuberculin Skin Tests (TST):

    TST, also known as the Mantoux test, involves injecting a small amount of purified protein derivative (PPD), a component of the tuberculosis bacterium, just beneath the skin. After 48 to 72 hours, a healthcare professional measures the size of the induration (raised bump) at the injection site. The size of the induration indicates the body’s immune response to the PPD and helps determine if the individual has been exposed to TB.

  2. Interferon-Gamma Release Assays (IGRAs):

    IGRAs are blood tests that measure the release of interferon-gamma, a substance produced by the immune system when exposed to TB-specific antigens. The two main types of IGRAs are the QuantiFERON-TB Gold In-Tube (QFT-GIT) test and the T-SPOT.TB test. These tests are more specific and less likely to be affected by prior Bacillus Calmette-Guérin (BCG) vaccination compared to TST.

Who Should Get Tested for LTBI?

LTBI testing is recommended for individuals who are at an increased risk of developing active TB disease. This includes:

  • Close Contacts of Active TB Cases: Individuals who have been in close contact with someone diagnosed with active TB disease.
  • Healthcare Workers: Healthcare professionals who are in contact with patients and are at risk of exposure to TB.
  • Immigrants and Refugees: Individuals coming from countries with a high prevalence of TB.
  • People with Weakened Immune Systems: Individuals with conditions such as HIV, diabetes, or those undergoing immunosuppressive therapy.
  • Correctional Facility Inmates: Due to the close living conditions in these settings, the risk of TB transmission is higher.

Conclusion

Testing for latent tuberculosis infection is a vital step in preventing the progression of TB from a latent state to an active disease. Early detection and treatment of LTBI can significantly reduce the burden of TB on both individuals and communities. Healthcare professionals, policymakers, and individuals themselves play a crucial role in recognizing the importance of LTBI testing and ensuring its implementation. Through comprehensive testing programs, coupled with effective treatment, we can move closer to a world where TB is no longer a widespread public health concern.